Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis

International Journal of Dermatology

Volumn 53, Issue 7, 2014, Pages 909-911

  Navarro, Raquel ^a   Concha Garzón, María José ^a   Castaño, Carlos ^a   Casal, Cristina ^a   Guiu, Alba ^a   Daudén, Esteban ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; AMINOTRANSFERASE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HUMAN; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT DURATION; VIRUS REACTIVATION; ANTAGONISTS AND INHIBITORS; BLOOD; HEPATITIS B VIRUS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PSORIASIS; VERY ELDERLY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84902814399     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12313     Document Type: Article

References (15)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
2. Pérez-Alvarez R, Díaz-Lagares C, García-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 patients. Medicine (Baltimore) 2011; 90: 359-371.
3. Navarro R, Ibañes S, Llamas M, et al. Awareness about possible reactivation of HBsAg-negative patients when prescribing biological therapy. J Eur Acad Dermatol Venereol 2011; 25: 1232-1233.
4. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
5. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113: 3147-3153.
6. Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B infection in patients with B-cell non-Hodgkin's lymphoma. Ann Hematol 2008; 87: 475-480.
7. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 813-819.
8. Lee IC, Huang YH, Chu CJ, et al. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010; 73: 156-160.
9. Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285-289.
10. Kim YJ, Bae SC, Sung YK, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37: 346-350.
11. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179.
12. Kato M, Atsumi T, Kurita T, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. J Rheumatol 2011; 38: 2209-2214.
13. Prignano F, Ricceri F, Pescitelli L, et al. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011; 164: 645-647.
14. Lalazar G, Rund D, Shouval D, et al. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
15. Lau GK, Hepatitis B. reactivation after chemotherapy: two decade of clinical research. Hepatol Int 2008; 2: 152-162.